LG AI Research and D&D Pharmatech are collaborating to use artificial intelligence for designing oral peptide therapeutics, combining AI-driven molecular discovery with proprietary formulation technology to improve bioavailability and reduce development timelines. This partnership addresses a critical gap in drug delivery: the difficulty of administering peptides orally, which could expand treatment options for diseases currently managed only through injection.
Key Points
- AI models will design peptide candidates by analyzing disease-agent structures
- D&D's ORALINK platform improves oral bioavailability and absorption efficiency
- Iterative validation refines AI models for faster, lower-cost drug development
Longevity Analysis
Peptide therapeutics represent a growing class of drugs for age-related and chronic diseases, but their oral delivery has been a limiting factor. By combining computational design with advanced formulation, this partnership could accelerate access to peptide-based treatments for precision medicine applications. The feedback loop between AI validation and model refinement creates a scalable system for discovering molecules tailored to individual disease profiles and metabolic responses — moving from one-size-fits-all therapeutics toward interventions aligned with individual biochemistry. Shorter development timelines and lower costs also reduce barriers to therapeutic innovation in areas where unmet medical need is high.
Original published by LT Wire.